GLP-1 drugs, Tylenol Texas lawsuit, NIH: Morning Rounds
The National Institutes of Health (NIH) recently faced controversy over the changing of grant titles, despite there being no formal list of banned words or phrases. More than 700 multiyear grants were altered from 2024 to 2025, with many edits involving the removal of words like “equity” and “disparities” that have been criticized by the Trump administration. This has raised concerns among researchers about the impact of these changes on the direction of their projects and the questions they are able to address. The process has been described as demoralizing and ambiguous, with one NIH program officer expressing frustration over the lack of transparency.
In another development, Texas Attorney General Ken Paxton filed a lawsuit against the makers of Tylenol, accusing them of deceptively marketing the drug to pregnant women and making unproven claims about its link to autism risk. The lawsuit alleges violations of Texas consumer protection laws and fraudulent transfer of liabilities by Johnson & Johnson. The case is set for a jury trial in a rural county in East Texas.
A study published in PNAS Nexus examined the impact of opt-out policies on organ donation rates in different countries. While opt-out programs have been shown to increase deceased organ donation rates, there has been a significant decrease in living donors, particularly altruistic donations. The researchers suggest that better communication about the need for living donors is essential to address this imbalance.
On the topic of weight loss drugs, a video by STAT’s Alex Hogan explores the potential for trademark erosion of the drug Ozempic. The video discusses the concept of genericide and the challenges faced by trademark lawyers in maintaining the distinctiveness of brand names in the pharmaceutical industry.
In a thought-provoking First Opinion essay, Valerie Black discusses the language used to describe the societal impact of AI chatbots. Black argues that terms like “AI psychosis” sensationalize and trivialize the issue, shifting focus away from addressing the underlying problems. Additionally, two researchers and clinicians highlight the importance of discussing chatbots with patients in healthcare settings.
Overall, these developments highlight the complex and evolving landscape of health and medicine, with legal challenges, ethical considerations, and communication strategies playing crucial roles in shaping the future of healthcare.
